However, the development of triple ACE/ECE/NEP inhibitors may be obstructed by negative conclusions about endothelin-1 receptor antagonists from large HF trials and practical concerns about the safety with ACE/NEP inhibitors. The gene discussed is ACE; the disease is hydrops fetalis.